Vardenafil: update on clinical experience
by
Pryor J.
Institute of Urology, London University,
and The Lister Hospital, London, UK.
Int J Impot Res 2002 Feb;14 Suppl 1:S65-9

ABSTRACT

Vardenafil, a potent and selective phosphodiesterase 5 inhibitor, has entered phase 3 clinical trials. Pharmacodynamic studies showed that the maximum plasma concentration after oral administration of 20-40 mg of vardenafil occurred in 0.7-0.9 h, the half-life was 4-5 h, and negligible amounts remained in the circulation after 24 h. The efficacy of vardenafil compared with placebo was shown in RigiScan studies, a phase 2 study involving 601 men with mild-to-severe erectile dysfunction for at least 6 months, and a phase 3 study involving 452 diabetic men. Adverse effects were not severe and tended to decrease with time.

Vardenafil
Apomorphine
Testosterone
Phentolamine
Coolidge effect
Sexual pharmacology
Vardenafil for diabetics
Love, lust and romance
Vardenafil and the heart
New sex-drugs: PDE-5 inhibitors
The pharmacology of penile erection
Tadalafil(Cialis) and sexual intercourse
Viagra v Levitra as recreational sex-drugs
Sexual health : drug combination therapies
Vardenafil (Levitra, Nuviva) and sexual satisfaction
Vardenafil (Levitra): prescribing information (PDF)
Vardenafil (Levitra, Nuviva) and penile tumescence

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family